You are here: Industry Insights > Univercells

News List

Univercells, RoosterBio Partner to Optimize Manufacturing of Extracellular Vesicles contractpharma
January 21, 2022
Aim to leverage scalable, continuous bioprocessing technologies to deliver regenerative therapies at reduced timelines and costs.
Univercells Acquires Biotechnology Company SynHelix contractpharma
January 06, 2022
SynHelix’s offering will complement the RNA platform being developed by Quantoom Biosciences SA.
Univercells Technologies Names CEO contractpharma
March 18, 2021
Univercells S.A. and Gamma Biosciences have appointed Mathias Garny as the Chief Executive Officer of Univercells Technologies, a global provider of next-gen bioprocess technologies.
Univercells, Univercells Technologies and Gamma Biosciences announce Mathias Garny as new CEO of Univercells Technologies PharmaSources.com
March 16, 2021
Univercells S.A., Univercells Technologies, and Gamma Biosciences are pleased to announce that effective March 15, 2021, Mathias Garny has been appointed as the Chief Executive Officer of Univercells Technologies, a Univercells company and global ...
Exyte and Univercells Join Forces contractpharma
May 15, 2020
Partner for rapid deployment of vaccine production plants in the wake of the COVID-19 crisis.
Univercells Launches Cell & Gene Therapy CDMO Exothera contractpharma
March 23, 2020
Will partner with innovators to unlock their manufacturing potential by capitalizing on best-in-class manufacturing technologies and bioprocessing expertise.
Univercells launches cell & gene therapy contract development and manufacturing organization (CDMO) Exothera with GMP capabilities in 15,000m² site in Jumet, Belgium Univercells
March 20, 2020
Exothera will partner with cell & gene therapy innovators to unlock their manufacturing potential by capitalizing on best-in-class manufacturing technologies and bioprocessing expertise.
Univercells Applies Modular Laboratory Concept at Nivelles, Belgium Site Univercells
October 23, 2019
In Q3 of 2019, Univercells completed a 400m2 extension to their Nivelles, Belgium site to support viral development.
Univercells Introduces Vaccine Manufacturing Platform americanpharmaceuticalreview
January 14, 2019
Univercells announced the commercial launch of its proprietary NevoLine bioproduction system for vaccines. The system was initially developed as part of a $12 million Grand Challenges grant awarded by .....
Univercells raises $18.8M to commercialize low-cost biologics manufacturing platform fiercevaccines
July 23, 2018
Right after releasing positive results for its novel affordable vaccine manufacturing technology, Belgium’s Univercells closed a €16 million ($18.8 million) series B backed by funds on three continents.

Previous page 1 2 Next page